Purpose. The results of a survey to characterize oncology drug shortages across the United States and the impact of shortages on clinical practice, patient safety, clinical trials, and health care costs are presented. Methods. A 34-item online survey was distributed to 1672 members of the Hematology/Oncology Pharmacy Association and other organizations to gather information on shortages of oncology drugs (i.e., all drugs essential in the care of cancer patients, including supportive care agents). Results. Two hundred forty-three completed responses, almost all from pharmacists (97%), were analyzed. Delays in chemotherapy administration or changes in treatment regimens due to drug shortages were reported by 93% of survey participants; 85% of respondents reported increased costs, and 10% reported reimbursement challenges related to drug shortages. At 34% of represented institutions, at least Ali McBride, Pharm.D., M.S., BCPS, is Specialty Practice Pharmacist-Hematologic Malignancies/Stem Cell Transplant,
1000 hours of additional labor annually was needed to manage shortages. Changes in therapy leading to near-miss errors were reported by 16% of participants, with 6% reporting one or more actual medication errors attributable to a drug shortage. The oncology medications most frequently reported to be in short supply during the preceding 12 months were fluorouracil, leucovorin, liposomal doxorubicin, and paclitaxel. The conduct of clinical trials was affected by drug shortages at 44% of represented institutions. Conclusion. A survey of U.S. oncology pharmacists indicated that oncology drug shortages occurred frequently in the first half of 2011. Shortages led to delays in chemotherapy and changes in therapy, complicated the conduct of clinical research, increased the risks of medication errors and adverse outcomes, and increased medication costs. Am J Health-Syst Pharm. 2013; 70:609-17 D rug shortages are a clear and growing challenge. A record 267 shortages occurred in the United States in 2011, more than in any other year. 1 Prominent among these were shortages of oncology medications and supportive care products essential for the care of cancer patients.
An extensive analysis of drug shortage data found that most shortages occur in the supply chain of generic injectable drugs, with shortages most frequently affecting supplies of oncology and antiinfective therapies. 2 Data from the Food and Drug Administration (FDA) indicate that quality issues at the site of manufacture are the most common cause of drug shortages (43%), and these are often serious issues, such as contamination by glass shards or fungi. 3 A number of oncology agent shortages gained national media attention; of particular note were shortages of methotrexate and liposomal doxorubicin. [4] [5] [6] Oncology drug shortages often result in disruptions in the timing of chemotherapy treatments, alterations in the dose or regimen administered, or even missed doses when alternative agents are unavail-able. 7 Both the safety and quality of cancer care are threatened by these occurrences. In many cases, equivalent therapeutic substitutions for certain medications are unavailable or unknown. 8, 9 The use of alternative medications due to shortages of preferred agents poses the risk of a suboptimal treatment response; the efficacy of alternative therapies may not be supported by the same level of evidence as established therapies, or they may carry an increased potential for adverse events. Beyond the patient care implications, shortages lead to higher costs when otheroften more expensive-drugs must be purchased at increased prices. 7, 10 Pharmacists and other hospital staff also must dedicate time to finding and procuring substitutes. 7 Multiple surveys, including those developed by the Institute for Safe Medication Practices (ISMP), American Society of Health-System Pharmacists, and American Hospital Association, have characterized the frequency of drug shortages and their negative impact on patient care. [11] [12] [13] [14] However, these surveys have not specifically focused on the impact of the increasing scarcity of oncology medications on the care of patients with cancer. To evaluate the effect of oncology drug shortages on patients with cancer, we devised and distributed a survey directed to oncology pharmacists and other health care professionals involved in managing drug shortages affecting patients with cancer. The purpose of this survey was to characterize the impact of oncology drug shortages across the United States, including the experiences of health care organizations, resource implications, and the impact on patient safety, patient care, and clinical trials.
Methods
A 34-item survey was developed and sponsored by the Hematology/ Oncology Pharmacy Association (HOPA). Members of the HOPA legislative affairs and membership committees developed and pilot tested the electronic survey. The survey was deployed using the Web-based survey tool Zoomerang (SurveyMonkey, Palo Alto, CA) and targeted pharmacists and other health care professionals involved in the care of patients with cancer. Requests to participate were sent via e-mail to all 1672 members of HOPA. The survey was also distributed using various methods to an undetermined number of recipients by ISMP, the Oncology Pharmacy Education Network of the Association of Community Cancer Centers, and the American Society of Clinical Oncology.
The electronic invitation included the purpose of the survey, a description of HOPA, and a link to the survey instrument. The invitation noted that participation was voluntary and confidential and that data would be disclosed only in aggregated form so that individual participants and institutions would not be identifiable. Participants were requested to complete only one survey per institution and to complete the survey as a coordinated group of oncology pharmacists, oncology nurses, purchasing staff, and others routinely involved in procuring, dispensing, and administering oncology medications. Data collection began on September 28, 2011, and closed on October 28, 2011. To encourage survey completion, two electronic reminders were sent to HOPA members before the closing date.
The demographic and facility data collected via the survey included the method of communication by which participants were informed about the survey, the primary role of the participant(s) in patient care, facility type, facility geographic location, whether or not the facility had an infusion center, the amount of chemotherapy administered per institution, and administration of outpatient and inpatient chemotherapy.
For this survey, the term oncology drug was broadly defined to include all drugs essential in the care of cancer patients, including chemotherapy and supportive care agents. The survey included questions regarding the percentage of the institution's medication shortages affecting cancer care, the frequency of new shortages on a monthly basis, and changes in the number of shortages as compared with the previous year. To assess the resource implications of oncology shortages, the survey included questions about increased costs due to shortages, including increased costs resulting from purchasing on the "gray" or "parallel market" (a supply channel that is unofficial, unauthorized, or unintended by the original manufacturer). Participants were also asked about reimbursement issues involving drugs in short supply, personnel time spent resolving oncology drug shortages, and new personnel hires to manage shortages. To assess the impact of oncology drug shortages on patient safety, participants were asked about medication errors, including nearmiss errors (i.e., errors that did not reach a patient), and adverse patient outcomes due to drug shortages.
To evaluate the patient care impact of oncology drug shortages, the survey included a list of disease states, and participants were asked to select those for which therapy for one or more patients was delayed or changed due to an oncology drug shortage. If shortages were experienced, participants were asked to list the top three chemotherapy medications or supportive care agents that were the most difficult to obtain. To further evaluate the impact of drug shortages on four specific disease states, the survey included questions on the approach to treating patients with cancers for which standard therapies were known to be in short supply at the time of the survey (liposomal doxorubicin, paclitaxel, fluorouracil, and cytarabine). Questions were also asked to assess the impact of drug shortages on clinical trials.
Results
A total of 243 usable survey responses were received, 83% (n = 201) of which were from HOPA members, and pharmacists were the primary participants (97%). As shown in Table 1 , participants represented practice sites across the United States. The majority of participants represented community hospitals (41%) and academic medical centers (39%).
Data on respondent and facility characteristics are provided in Table  1 . Most survey participants, 97% (n = 235), reported that their institution had an onsite infusion center, 201 (83) 16 (7) 9 (4) 17 (7) 236 (97) 2 (1) 5 (2) 94 (39) 100 (41) 15 (6) 12 (5) 9 (4) 2 (1) 13 (5) 15 (6) 24 (10) 48 (20) 14 (6) 41 (17) 18 (7) 14 (6) 26 (11) 43 (17) 199 (82) 187 (77) 22 (9) 77 (32) 63 (26) 67 (28) 14 (6) with the majority of represented facilities providing both outpatient and inpatient chemotherapy (only 44 institutions did not provide inpatient chemotherapy). Fifty-nine percent (n = 144) of the survey participants reported that at least 500 doses of chemotherapy were administered each month at their institution.
Characteristic

Survey Respondent Demographics and
Experiences with oncology drug shortages. Over the 12-month period before distribution of the survey, 98% (n = 239) of participating institutions experienced at least one drug shortage. Compared with the 2010 calendar year, 97% (n = 235) of all participants reported an increase in drug shortages relating to oncology treatments in 2011. Additionally, 93% of survey respondents (n = 227) reported a delay in the administration of chemotherapy or a change to a different treatment regimen for one or more disease states due to shortages, and 220 specified the areas of cancer treatment most often affected; delays were most frequently reported in the treatment of patients with ovarian cancer (52%), colorectal cancer (51%), breast cancer (49%), and acute myeloid leukemia (AML) (35%).
When participants were asked to estimate the percentage of the total number of drug shortages experienced by their institution that involved oncology-related medications, 60% of participants (n = 146) estimated that figure as at least 20%, with 16% (n = 39) estimating the proportion at greater than 80%. Of the total of 243 participants, 239 reported that the medications that were the most difficult to obtain a Respondents asked to identify three most difficult drugs to obtain at time of survey. b Magnesium sulfate (n = 6), methotrexate (n = 6), busulfan (n = 5), dexamethasone (n = 5), idarubicin (n = 4), foscarnet (n = 3), mesna (n = 3), carboplatin (n = 2), mechlorethamine (n = 2), prochlorperazine (n = 2), vincristine (n = 2), asparaginase (n = 1), calcium (n = 1), carmustine (n = 1), cyanocobalamin (n = 1), denileukin difitox (n = 1), dexrazoxane (n = 1), famotidine (n = 1), oxaliplatin (n = 1), and thyrotopin alfa (n = 1).
(54)
95 (40) 92 (38) 92 (38) 78 (33) 44 (18) 41 (17) 41 (17) 19 (8) 13 (5) 12 (5) 12 (5) (Table 2) .
Resource implications of oncology drug shortages. Approximately 34% of participants reported that their facilities had dedicated 1000 or more personnel hours to managing oncology drug shortages in 2011; this equates to at least 0.5 full-time equivalent staff resource unit, or approximately 20 hours each week. Despite the increase in personnel hours allocated to manage the shortages, only 4% of respondents (n = 10) reported that their institution had hired additional personnel. Seven participants reported hiring at least 1 full-time employee.
The survey data indicated that in addition to a need for increased personnel resources, oncology drug shortages resulted in increased costs for 85% (n = 206) of the 243 survey participants' institutions, with reimbursements issues related to the use of substitute products experienced by 10% (n = 24) of the institutions. Levoleucovorin and paclitaxel or albumin-bound paclitaxel were mentioned most frequently when participants were asked to elaborate on the medications involved with these reimbursement challenges.
One common source of increased costs for drugs in short supply is the gray market. Twenty-eight percent (n = 69) of survey participants reported purchasing products from the gray market. The prices of the products varied considerably; 14% of respondents (n = 35) reported paying at least 100% over fair market value.
Patient safety implications of drug shortages. With the increase in oncology drug shortages, alternative regimens are being used. Use of these less-familiar medications can lead to medication errors or patient harm. Near-miss medication errors (i.e., errors that did not reach the patient) were reported by 16% (n = 39) of survey participants during the past year due to an oncology drug shortage. As shown in Table 3 , wrong-drug errors, incorrect dosing conversions, and the use of the wrong concentration of medication collectively accounted for 74% (n = 29) of these near-miss medication errors.
Survey respondents attributed the majority of wrong-drug errors to shortages of liposomal doxorubicin, the majority of incorrect dosing conversions to leucovorin shortages, and the majority of wrong-concentration errors to cytarabine shortages.
Examples of near-miss medication errors included incorrectly converting i.v. etoposide doses to equivalent amounts of oral etoposide or etoposide phosphate, ordering of liposomal doxorubicin in place of doxorubicin, mixing of multiple concentrations of cytarabine, and incorrectly converting a prescribed dose of leucovorin to an equivalent dose of levoleucovorin.
In addition to near-miss medication errors resulting from oncology medications in short supply, medication errors that reached a patient were also reported. Six percent (n = 15) of participants described errors associated with alternatives to standard therapy. Some of these events included administering an incorrect dose of levoleucovorin (used as a substitute for leucovorin), miscalculating the dose of capecitabine when fluorouracil was unavailable, performing incorrect conversions from i.v. leucovorin to oral leucovorin (in equal concentrations), and using doxorubicin in place of liposomal doxorubicin despite a lack of data supporting such substitutions (Table 3) . [15] [16] [17] According to one survey respondent, a patient death was attributed to incorrect medication dosing as a result of conversion to epirubicin therapy during a daunorubicin shortage.
Adverse patient outcomes as a result of a drug shortage were also reported. Sixteen percent of participants (n = 40) described adverse patient outcomes that they believed to be related to drug shortages. The reported adverse events included delays in treatment with liposomal doxorubicin that were thought to have led to disease progression, increased adverse effects associated with conversions from i.v. fluorouracil to oral capecitabine therapy (e.g., colitis, diarrhea, hand-and-foot syndrome), increased cardiac events attributed to switching from doxorubicin to epirubicin and from liposomal doxorubicin to doxorubicin, amplified adverse effects (e.g., headache) with the use of increased concentrations of carmustine in stem cell transplantation because of a change in conditioning regimens, and increased adverse effects after switching from paclitaxel to docetaxel.
One survey respondent reported that two patients developed encephalopathy during a shortage of an i.v. multivitamin that necessitated a switch to oral multivitamins that did not contain thiamine or that the patients did not take appropriately.
Patient care implications for cancer care. Drug shortages are particularly challenging in oncology because, in many cases, little or no information on alternative regimens exists. The survey results indicate that drug shortages have led to changes in regimens, the omission of unavailable treatments, delays in chemotherapy, and even importation of medication. Survey participants also provided information on current practices for dealing with shortages affecting patients with the four previously mentioned disease states: metastatic ovarian cancer, breast cancer, colorectal cancer, and AML (Table 4) .
Liposomal doxorubicin is a mainstay of therapy in the treatment of ovarian cancers (it is also indicated for multiple myeloma and AIDSrelated Kaposi's sarcoma) and was in shortage at the time the survey was conducted. 18 Survey participants reported several mechanisms for handling this situation: 34% (n = 84) used an alternative therapy, 27% (n = 66) used conventional doxorubicin in place of liposomal doxorubicin, and 17% (n = 42) omitted liposomal doxorubicin from the 11 (28) 10 (26) 8 (21) 3 (8) 3 (8) 4 (10) 2 (13) treatment regimen without a substitution. The primary agent used as an alternative therapy was gemcitabine; bevacizumab, carboplatin, doxorubicin, docetaxel, oral etoposide, ixabepilone, paclitaxel, topotecan, and vinorelbine were also reported as possible alternatives. Given its efficacy, tolerability, and predictable adverse effect profile, paclitaxel has become a cornerstone in the treatment of both early-stage and metastatic breast cancer, either as monotherapy or in combination with a variety of other agents, including trastuzumab for tumors expressing human epidermal growth factor receptor 2. 19, 20 In addition to its use in breast cancer, paclitaxel is used to treat numerous other types of cancers, such as ovarian, bladder, esophageal, lung, and head and neck cancer. 21 During the shortages of this medication, 20% (n = 49) of survey participants reported changing to a different medication, such as proteinbound paclitaxel and docetaxel. Eleven percent (n = 28) of participants reported obtaining paclitaxel from another institution, while 3% (n = 8) indicated that arrangements were made for patients to receive the drug at other institutions that still had a supply. Four percent (n = 9) of the institutions reduced the dose of paclitaxel administered to each patient to conserve their on-hand quantity. According to one respondent, a facility used the gray market to replenish its supply.
Fluorouracil is another frequently used medication in numerous oncological disease states, including colorectal cancer. 22, 23 During the shortages, 32% of institutions (n = 78) changed to a different therapy or treatment regimen such as capecitabine-based therapy with or without the addition of oxaliplatin. Fluorouracil dose reductions were reported by 9% of survey participants (n = 23). Additional practices reported by survey participants included restricting the use of fluorouracil to specific disease states, obtaining the medication via the gray market, and delaying treatment until the medication became available.
Cytarabine, a therapy used to treat hematologic malignancies (most commonly AML but also acute lymphocytic leukemia and non-Hodgkin's lymphoma), has frequently been in short supply. 9, 24 There is no therapeutic equivalent to cytarabine for AML, and evidence suggests that delayed induction therapy or interruption of maintenance therapy, as can occur during cytarabine shortages, may be associated with adverse outcomes, such as death and a shortened duration of remission. 9 Whether a similar outcome may occur with cytarabine interruption in patients with other hematologic diseases is unknown. 9 Twelve percent (n = 29) of participants reported changing the standard regimen to another therapy or regimen, such as clofarabine, the "5 + 2" regimen (five days of cytarabine combined with two days of an anthracycline), the EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and predisone) regimen, decitabine, MEC (mitoxantrone, etoposide, and cytarabine) therapy, and etoposide-cytarabine chemotherapy, or deleting cytarabine from existing regimens (e.g., MEC-based chemotherapy regimens) to facilitate treatment; there are no published data to support these regimens as equivalent therapy. Some institutions (10%) reported sending cytarabine to a patient at another institution or accepting patients from other institutions that could not obtain cytarabine (16%). Dosage reductions of cytarabine in an effort to conserve the supply for future doses or other patients were reported by 11% of participants (n = 28).
Impact of drug shortages on clinical trials. During a shortage, clinical trial enrollment may be suspended until the medication is available or protocol modifications may be required. In our survey, 44% (n = 108) of institutions reported that drug shortages affected clinical trials, mainly experienced as delays in patient enrollment (44%) or not enrolling patients at all (67%). Survey participants reported changes to the medications used in the research, complete omission of a medication from a protocol, and even stockpiling Changed to another regimen Sent patient to another institution for treatment Omitted drug without substitution Converted to another form of drug for treatment Reduced dosage of drug for treatment Obtained drug from another institution Obtained drug, no effect on practice Unknown or did not treat (16) 113 (47) 54 (22) 78 (32) d 4 (2) 18 (7) NA 23 (9) 19 (8) 131 (54) 25 (10) 49 ( (57) 36 (15) 84 (34) b 16 (7) 42 (17) 66 (27) NA 18 (7) 30 (12) 63 ( medications (often at the expense of nonresearch patients) to ensure that a clinical trial could be completed.
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Discussion
Drug shortages pose a serious risk to the health care system. [11] [12] [13] 25 Oncology drug shortages are a particular concern that affects numerous institutions and patients. 26, 27 Managing oncology drug shortages continues to be a challenging task that requires increased efforts and difficult decisions by health care providers. The temporary unavailability of oncology drugs has added to the complexity of treating specific cancers and resulted in adverse outcomes for patients, including reported increases in adverse effects and disease progression. Oncology drug shortages may be more challenging than shortages in other therapeutic areas, as therapeutic alternatives for which there is equivalent supportive evidence may not exist. Using therapeutic alternatives that are not considered equivalent may result in lower cure rates and disease control.
The resource implications of drug shortages have been felt across the U.S. health care system. 28, 29 The increased time and effort required to maintain an adequate supply of these medications, in addition to heightened demand, have resulted in increased costs for both health systems and patients. 30 One survey indicated that the overall cost of drug shortages to U.S. hospitals forced to purchase more expensive substitutes is $200 million annually, and another survey indicated that the labor costs associated with managing shortages in the United States are as high as $216 million. 12, 31 The survey described here evaluated the resource implications of shortages of 25 oncology agents and showed that oncology drug shortages increase costs. More than 80% of institutions reported incurring increased costs due to oncology drug shortages, with approximately 28% of those surveyed resorting to gray market products, which are often more expensive and may also contribute to drug shortages. The reallocation of existing staff to manage shortages was commonly reported, with 34% of participants devoting approximately 20 hours or more per week to mitigate drug shortages. Due to the limited resources available during a drug shortage, other services may need to be decreased in order to offset the resource costs of oncology drug shortages; this has the potential to increase overall health care costs at the same time there is a national focus to reduce overall health care expenditures.
Although not formally evaluated in our survey, the use of more expensive alternative agents due to drug shortages can increase direct costs and alter reimbursement. 30 For example, if patients are forced to switch from a generic to a brandname product, costs increase and institutions may have trouble being reimbursed for alternative therapies (e.g., switching from leucovorin to levoleucovorin). In other situations, alternative regimens used during shortages may require an inpatient admission for drug administration because of the potential toxicities associated with the regimen (e.g., a shortage of bleomycin for testicular cancer may require admission for VIP [etoposide, ifosfamide, and cisplatin] therapy), which may increase overall health care costs, some of which may be passed on to the patient.
During a drug shortage, it is common practice to select an alternative agent in order to avoid delays in treatment in the event standard therapies are unavailable. Such changes in therapy have the potential to lead to medication errors or harm to the patient. Cancer, unlike many other disease states, is treated with specific multidrug regimens with narrow therapeutic indexes. Slight changes to a chemotherapy regimen (e.g., using a lower dose to conserve supply, substituting a medication from a similar therapeutic class) have the potential to result in adverse patient outcomes. According to previously published survey reports, drug shortages have the potential to contribute to medication errors when unfamiliar alternative agents are used; moreover, little data exist on the efficacy of many alternatives to oncology medications in scarce supply. 11, 12 Near-miss errors were reported by 16% of the respondents to the survey; in addition, 6% reported the occurrence of actual medication errors. These data are similar to those reported by ISMP, which conducted a national survey of more than 1800 health care providers in 2010.
11 ISMP identified at least 1000 near-miss incidents, medication errors, and adverse patient outcomes due to drug shortages over the preceding 12 months. In the ISMP survey, 20% of participants reported that adverse patient outcomes due to drug shortages had occurred for a variety of reasons. In some situations, alternative medications were not available. A follow-up survey by ISMP, conducted in late 2011, noted that chemotherapy medications were the most frequent type of medication associated with adverse events related to shortages (27%), with 35% of respondents reporting inadequate treatment secondary to drug inavailability. 14 Using alternative agents or modifying the dosage within a cancer treatment regimen has the potential to result in reduced effectiveness compared with the original regimen. Although outcome data are lacking, many health care providers have the perception that changes in therapy during drug shortages such as those described above may be affecting patient outcomes. A recently completed survey indicated that nearly half of U.S. oncologists had observed poorer outcomes in their patients during drug shortages 32 ; of those surveyed, 48% reported tumor recurrences, and 40% reported cases of decreased time to death.
In our survey, up to one third of survey participants reported switching to an alternative regimen during drug shortages (Table 4) . Delays in therapy until a drug becomes available can last from days to months, which may also limit a patient's chance for a cure or disease remission. In our survey, 93% of the institutions reported delays in chemotherapy administration or regimen changes secondary to drug shortages. Delays were more common in patients with ovarian cancer, colorectal cancer, breast cancer, or AML. Further research is needed to fully evaluate and understand the impact of alternative therapies during a drug shortage.
Nearly 50% of the participants in our survey reported a negative impact on clinical trials at their institution due to shortages in oncology medications. Such shortages can result in important clinical trials being delayed or suspended, as well as the halted accrual of new patients. [33] [34] [35] In some cases, clinical trial sponsors have been placed in the difficult position of using alternative regimens that are not part of the original protocol due to a shortage of the medication under investigation. Drug shortages clearly add to the complexity of clinical research, and, while difficult to definitively quantify, oncology drug shortages may cause delays in obtaining the data necessary to bring new cancer therapies to patients.
Our survey underscored the need for policy changes to mitigate oncology and other drug shortages. The Food and Drug Administration Safety and Innovation Act, also referred to as the FDA user fee reauthorization, was signed into law by the President on July 9, 2012, and includes several drug shortage provisions. 36 Drug manufacturers will be required to notify FDA at least six months (or as soon as possible) before any discontinuance or interruption in the production of drugs that are life-supporting or lifesaving agents or are intended for use in the prevention of a debilitating disease or condition. FDA will have the responsibility to disseminate information regarding discontinuance or interruptions in drug manufacturing to health care providers. The law includes several other provisions aimed at mitigating drug shortages, including expedited review and inspections by FDA when necessary to help avoid a pending shortage, the creation and maintenance of a drug shortage list by FDA, adjustments in the quotas for controlled substances if needed to avoid a drug shortage, and allowing hospitals to repackage a drug to increase the supply; in addition, the law requires several reports by FDA and the Government Accountability Office to Congress on the effectiveness of regulations and guidance in mitigating drug shortages. The negative impact of oncology drug shortages is clear from our data; therefore, these policy changes will need to be monitored carefully to determine if they are successful in mitigating the impact of oncology drug shortages on cancer care.
Further policy actions, such as economic incentives, may be needed to return to a stable and consistent oncology drug supply. However, economic analysis indicates that the supply of sterile injectable drugs on the market is insensitive to shortterm price changes and that the lack of manufacturing capacity is a fundamental reason for drug shortages. 37 Therefore, economic incentives to address shortages of sterile injectable drugs may be best targeted with the goal of increasing manufacturing capacity.
Our study had several limitations. Because the survey respondents consisted primarily of pharmacist members of HOPA, our data may not be representative of cancer care across the United States. However, as Table  1 indicates, responses were received from a variety of practice settings and geographic areas. While our sample size provided a basic characterization of oncology drug shortages in the United States, we did not have an adequate number of responses to provide meaningful information on important demographic features, such as practice setting or geographic region. The dynamic nature of drug shortages makes it difficult to characterize outcomes and challenges associated with the shortages, because responses represent a "snapshot" in time. Additionally, drug shortage information changes constantly, so we cannot be certain that survey participants had complete information about the impact of the shortages within their institution.
Conclusion
A survey of U.S. oncology pharmacists indicated that oncology drug shortages occurred frequently in the first half of 2011. Shortages led to delays in chemotherapy and changes in therapy, complicated the conduct of clinical research, increased the risks of medication errors and adverse outcomes, and increased medication costs.
